Consistently, patients with BIRC3 mutations treated with FCR have the same poor outcome as patients with TP53 disruption, which represents the strongest predictor of chemorefractoriness in CLL [28]. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.